Burzynski Research Institute Inc represents a commitment to developing innovative and effective cancer therapies. With a focus on personalized medicine, the company aims to provide individualized treatment options for patients. They prioritize patient care and strive for advancements in oncology through clinical research and cutting-edge technology. Burzynski Research Institute Inc believes in a patient-centered approach, offering hope and personalized solutions to those battling cancer. By continuously exploring new treatment methods and maintaining a dedication to scientific excellence, the company aims to make a meaningful impact in the fight against cancer.

Burzynski Research Institute Inc is primarily present in the United States.

Some significant milestones achieved by Burzynski Research Institute Inc include the development of innovative cancer treatments, such as Antineoplastons, which have shown promising results in certain types of tumors. The company has also conducted numerous clinical trials and received FDA approval for certain treatment protocols. Furthermore, Burzynski Research Institute Inc has successfully defended its patents and treatments in legal battles, ensuring its continued research and development efforts. Its dedication to revolutionizing cancer therapy has garnered recognition and support from patients, medical professionals, and advocacy groups worldwide.

Burzynski Research Institute Inc. is a biopharmaceutical company founded by Dr. Stanislaw Burzynski in 1976. Dr. Burzynski is known for developing a non-toxic gene-targeted therapy called Antineoplastons, which has shown promise in treating various types of cancer. The company's focus lies in conducting clinical trials and providing personalized cancer treatment options to patients. With over four decades of experience, Burzynski Research Institute Inc. has been at the forefront of innovative cancer therapies and has made significant contributions to the field of oncology. The company continues to explore novel methods to combat cancer and improve patients' quality of life. Burzynski Research Institute Inc. is committed to revolutionizing cancer treatment through its research and dedication to patient care.

The main competitors of Burzynski Research Institute Inc in the market include other research institutes and pharmaceutical companies that specialize in cancer research and treatment. These competitors may include Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, Pfizer Inc, Novartis International AG, and Roche Holding AG.

Burzynski Research Institute Inc primarily operates in the healthcare industry.

The business model of Burzynski Research Institute Inc focuses on the development and commercialization of innovative and personalized cancer treatments. As a biopharmaceutical company, Burzynski Research Institute Inc utilizes anti-neoplaston therapy, which involves the use of compounds derived from naturally occurring peptides and amino acids. This therapy aims to target and inhibit cancer cell growth while minimizing side effects. By conducting research, clinical trials, and providing patient care, Burzynski Research Institute Inc aims to improve the lives of cancer patients through personalized medicine and further advancements in cancer treatment.

De Burzynski Research Institute K/W is -6,89.

De Burzynski Research Institute KUV is 0.

De AlleAktien Kwaliteitsscore voor Burzynski Research Institute is 4/10.

De omzet kan momenteel niet worden berekend voor Burzynski Research Institute.

De Burzynski Research Institute winst is -1,34 mln. USD.

The Burzynski Research Institute is a biotech company that has been active for over 40 years. They specialize in the research and development of cancer therapies using innovative approaches. The company operates in various areas such as research and development, clinical trials, diagnosis, and therapy. One important factor of Burzynski Research Institute's business model is the use of peptide-based therapies that aim to selectively destroy cancer cells without damaging healthy tissue. This includes specially designed peptides and antibodies that target proteins or genes specific to cancer cells. The company is also involved in the development of diagnostic tools, including receptors that serve as biomarkers to identify and measure the activity of cancer cells. This allows for more precise diagnosis and treatment of cancer. In addition to research and development, the institute is also involved in the clinical phase of studies to assess the effectiveness and safety of their drugs. Burzynski Research Institute has already achieved many successes in this field, including the development of a new therapy for the treatment of brain tumors. The business model of Burzynski Research Institute also relies on collaboration with other companies and partners. Over the years, the company has successfully established partnerships with other biotech companies, scientific institutions, and government agencies. The products of Burzynski Research Institute are primarily targeted at research institutions and healthcare organizations. The company produces peptides, antibodies, receptors, and other drugs that can be used in cancer research. In summary, the business model of Burzynski Research Institute focuses on the development of peptide-based cancer therapies that selectively target cancer cells while preserving healthy tissue. The company operates in various areas including research and development, clinical trials, diagnosis, and therapy. In addition to collaboration with other companies and partners, the company's products are specifically aimed at research institutions and healthcare organizations.

Burzynski Research Institute keert een dividend van 0 USD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Burzynski Research Institute of het bedrijf keert geen dividend uit.

De ISIN van Burzynski Research Institute is US1231591058.

Het WKN van Burzynski Research Institute is A0CA3Q.

De ticker van Burzynski Research Institute is BZYR.

Binnen de laatste 12 maanden betaalde Burzynski Research Institute een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Burzynski Research Institute naar verwachting een dividend van 0 USD betalen.

De dividendrendement van Burzynski Research Institute is momenteel .

Burzynski Research Institute betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Burzynski Research Institute betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 USD verwacht. Dit komt overeen met een dividendrendement van 0 %.

Burzynski Research Institute wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Burzynski Research Institute van 20-9-2024 ter hoogte van 0 USD te ontvangen, moest je het aandeel voor de ex-datum op 20-9-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 20-9-2024.

In het jaar 2023 heeft Burzynski Research Institute 0 USD aan dividenden uitgekeerd.

De dividenden van Burzynski Research Institute worden in USD uitgekeerd.